RNS Number : 9619J
Neuropharm Group PLC
09 April 2010
|
For Immediate Release
|
9 April 2010
|
Neuropharm Group Plc
("Neuropharm" or "the Company")
Board Change
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, announces that Dr Mike Snape is stepping down from his position as Chief Scientific Officer and from the board of the Neuropharm Group with effect from 9th April. The Board would like to thank Dr Snape for his considerable contribution as a founder of the Company and Chief Scientific Officer since its inception in 2005.
For further information please contact:
Neuropharm
|
+ 44 (0) 1372 371 171
|
|
Robert Mansfield, Chief Executive Officer
Graham Yeatman, Chief Financial Officer
|
|
|
|
|
Piper Jaffray Ltd.
|
+ 44 (0) 20 3142 8700
|
|
Neil Mackison, Rupert Winckler
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
|
Mark Court
|
|
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKKCDQKBKDFQK